Method for using inflammatory markers to guide anti-clever-1 based cancer treatment
AssigneeFaron Pharmaceuticals Oy
InventorsJuho JALKANEN, Teppo HUTTUNEN
Life of this patent
Estimating the term…
Abstract
A method for choosing a patient to anti-CLEVER-1 therapy prior to beginning anti-CLEVER-1 therapy using one or several of the inflammatory markers selected from interferon gamma (IFNγ), tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 8 (IL-8) and C-reactive protein. When the measured level of the inflammatory marker is substantially within the reference values of the inflammatory marker or lower than the average reference value of the inflammatory marker, it is an indication to choose the patient and begin the anti-CLEVER-1 therapy.
Claims9
A method for choosing a patient to anti-CLEVER-1 therapy prior to beginning anti-CLEVER-1 therapy, which anti-CLEVER-1 therapy comprises an administration of an agent capable of binding to CLEVER-1 in a patient, characterized in that the method comprises
- providing a blood sample obtained from the patient at a first point in time prior to beginning anti-CLEVER-1 therapy,
- measuring a level of one or more inflammatory marker selected from the group consisting of interferon gamma (IFNg), tumour necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 8 (IL-8) and C-reactive protein (CRP) from the obtained sample, and
- comparing the measured level of the inflammatory marker to a reference value of said inflammatory marker,
- wherein the measured level of the said inflammatory marker, which is substantially within the reference values of the inflammatory marker or lower than the average reference value of the inflammatory marker, is an indication to choose the patient and begin the anti-CLEVER-1 therapy.
Dependencies are inferred from the claim text.